VOR completes Phase III telitacicept enrollment; key readout set for early 2027
VOR says enrollment is complete for its Phase III telitacicept MG trial, with a key readout expected in early 2027. The company is expanding into ocular MG and Sjögren’s, highlighting a dual BAFF/APRIL mechanism.
Enrollment in the phase III telitacicept MG trial is complete, with a key readout expected in early 2027. The company is also expanding into ocular MG and Sjögren's, and is highlighting robust efficacy, durability and patient flexibility. It says telitacicept is differentiated by a dual BAFF/APRIL mechanism and strong sa…